Translating Science and Big Data into Saving Lives

2016 FH Global Summit Introduces Innovations That Impact Patient Care

News provided by

Oct 17, 2016, 10:26 ET

DALLAS, Oct. 17, 2016 /PRNewswire-USNewswire/ -- The Familial Hypercholesterolemia (FH) Foundation will be hosting its 2016 FH Global Summit in Dallas, Texas on October 17 and 18. In attendance will be keynote speakers, Nobel laureates Drs. Michael Brown and Joseph Goldstein. Their pioneering work led to the discovery of low-density lipoprotein (LDL) receptors and revolutionized our understanding of cholesterol metabolism and heart disease.

The FH Foundation's FH Global Summit convenes distinguished leaders in diverse fields to change the status quo for FH. With experts in cardiology, lipidology, biochemistry, health economics, bioinformatics, and public health, we are working toward a common goal to translate FH research into every day clinical practice that prevents premature cardiovascular disease.

Over 250 scientists, clinicians, public health professionals and key stakeholders will convene for two days, taking a deep-dive into the basic science of FH, physiology, pharmacology and clinical practice.

FH is a common, life-threatening genetic condition that causes early and aggressive coronary heart disease due to life-long exposure to elevated LDL cholesterol. Despite the scientific progress that has been made, FH remains vastly under-diagnosed and under-treated. To improve diagnosis rates, The FH Foundation initiated the FIND FH® project, a national initiative utilizing machine-learning algorithms applied to a HIPAA-compliant database of 89 million Americans with cardiovascular disease. During the Summit, the FH Foundation will unveil a cutting-edge interactive map for healthcare providers to learn about FH in their own community and practice.

"The revolutionary discoveries of Dr. Brown and Dr. Goldstein clearly demonstrated that LDL cholesterol is a driver of cardiovascular disease. Their work led to the first therapies to substantially reduce cholesterol, forever shifting our ability to prevent and delay the onset of heart disease." – Katherine Wilemon, Founder and CEO of the FH Foundation.

The FH Foundation is a 501(c)(3), patient-centered research and advocacy organization dedicated to increasing the rate of early diagnosis, encouraging proactive treatment and improving the quality of life of all those impacted by all forms of familial hypercholesterolemia.
www.theFHfoundation.org

Video - https://www.youtube.com/watch?v=0j5tKyPlz5I&feature=player_embedded

SOURCE The FH Foundation